2^nd Münster Vascular Symposium on 25^th March 2023 in Münster, Germany

29^th Bonn Vein Days from 31^st March to 1^st of April 2023 in Bonn, Germany

52^nd Meeting of the German Dermatological Society (DDG) from 26^th to 29^th of April 2023 in Berlin

DEWU German Wound Congress from 10^th to 12^th of May 2023 in Bremen, Germany

Please visit: https://ulcus-cruris-studie.de/

Our daughter company RHEACELL has been granted national marketing authorization (§ 4b of the German Medicinal Products Act) in Germany for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.

Drawing on over 15 years' experience in advanced stem cell research and regenerative medicine to pioneer the production of ABCB5-positive (ABCB5+) mesenchymal stem cells and innovative treatment pathways.

Using cutting-edge, in-house process technology and quality control systems to generate state-of-the-art ABCB5+ mesenchymal stem cells ("H.F.M Stem Cells") and ATMP (Advanced Therapy Medicinal Products) in line with AMG (German Medicinal Products Act) requirements.

Science-based mechanisms-of-action translated into GMP-validated potency assays and release criteria to predict clinical efficacy.

High through-put stem cell production based on globally patented technology and expertise - catering for world-wide market needs - anytime, anyplace, anywhere.

Our tried and tested patented technology platform nurturing next-generation technologies (CRISPR/Cas, iPS Technology and 3D Bioprinting), heralding the arrival of next-generation cell therapies.

TICEBA - exclusive licensee of the full ABCB5 patent portfolio from Boston Children's Hospital - a teaching affiliate of Harvard Medical School, Boston, Massachusetts. Several of these were invented at the same time and are jointly owned by TICEBA.